Immune monitoring of surgical colorectal malignancies through carcinoembryonic antigen and alpha-fetoprotein serum levels, flow-cytometric blood lymphocyte phenotyping and tumor DNA analysis.
67 patients with operable colorectal adenocarcinomas were divided into two groups based on criteria referring to DNA flow-cytometric models and the histopathological type and stage of intraoperatively harvested tumor samples: low-aggressive tumor group and highly aggressive tumor group. Two kinds of immunological markers were investigated: humoral (carcinoembryonic antigen and alpha-fetoprotein serum levels were measured by ELISA) and cellular (blood lymphocyte counts of the following subpopulations: CD3+, CD4+, CD8+/CD11b+, CD19+, CD16+/CD56+, HLA-DR+/CD3+, measured by means of flow cytometry). All assays were similarly performed before and 2, 4, 6 and 8 weeks after tumor exeresis. Results seem to reveal a relationship between patients without immunological recovering and a bad postoperative clinical evolution of the highly aggressive colorectal malignant tumors. The significance of multiway immune monitoring of colorectal cancer is discussed.